OSTX AMEX
OS Therapies Incorporated
1W: -1.8%
1M: -4.7%
3M: +1.2%
YTD: +21.6%
1Y: -18.5%
$1.62
+0.01 (+0.62%)
Weekly Expected Move ±7.2%
$1
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (23)
OS Therapies appoints Kerry Clem as CCO, Frank Knuettel II as CFO
OS Therapies (NYSEAMERICAN:OSTX) Stock Price Down 2.5% – Time to Sell?
OS Therapies GAAP EPS of -$0.20 misses by $0.03
12 Health Care Stocks Moving In Thursday's After-Market Session
OS Therapies Incorporated (OSTX) Q1 2026 Earnings: EPS Misses Estimates as Operating Losses Widen - Performance Review - newsline.com
OS Therapies Says New Bone Cancer Data Strengthens Case For Regulatory Filings
Earnings Scheduled For May 18, 2026
Guardant Health CMO resigns
Short Interest in OS Therapies Incorporated (NYSEAMERICAN:OSTX) Decreases By 16.7%
12 Health Care Stocks Moving In Thursday's After-Market Session
OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings
OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
OS Therapies Incorporated (NYSEAMERICAN:OSTX) Sees Large Growth in Short Interest
OS Therapies Bone Cancer Trial Data Strengthens FDA Case
OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of OS Therapies Incorporated (NYSE American: OSTX)
OS Therapies Provides First Half 2026 Corporate Outlook
OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma
OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility
OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization
Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25